Lenvatinib-Associated Fulminant Type 1 Diabetes Mellitus-Reference-Cited by-同舟云学术

Lenvatinib-Associated Fulminant Type 1 Diabetes Mellitus

Published:2022-03-24 Issue:6 Volume:30 Page:e561-e563
ISSN:1075-2765
Container-title:American Journal of Therapeutics
language:en
Short-container-title:

Author:

Liao Pei-Fei¹,Peng Tzu-Rong¹^ORCID,Wu Ta-Wei¹,Hu Ya-Hui²

Affiliation:

1. Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, China

2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu-Chi Hospital, Buddhist Tzu-Chi Medical Foundation, New Taipei City, Taiwan, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology,General Medicine

Reference7 articles.

1. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies;Imagawa;N Engl J Med.,2000

2. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute‐onset type 1 diabetes mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus;Imagawa;J Diabetes Investig.,2012

3. FGF/FGFR signaling in health and disease;Xie;Signal Transduct Target Ther.,2020

4. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models;Matsuki;Cancer Med.,2018

5. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus;Imagawa;J Diabetes Investig.,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib/sorafenib;Reactions Weekly;2024-06-01